Technion Labs Explore Quantum Computing and Cancer Treatment

The Technion is pushing the boundaries of science and engineering, focusing on future innovations rather than past achievements. Lihi Zelnik-Manor, the Technion's Vice President for External Relations and Resource Development, emphasizes that Artificial Intelligence (AI) is a tool for unlocking new possibilities, not an end goal. The institution is exploring what lies beyond current AI capabilities, with quantum technology being a key frontier.

In the field of quantum technology, Professor Yoav Sagi from the Physics Faculty is researching ultra-cold atom labs to develop quantum systems capable of complex calculations beyond the reach of conventional computers. He highlights the necessity of bridging the gap between fundamental science and engineering to translate quantum science into practical technology. Sagi describes quantum computers not as faster versions of current machines, but as entirely different systems designed for novel, complex computations, the full potential of which is still unknown.

Meanwhile, in the Wolfson Faculty of Chemical Engineering, Dr. Assaf Singer and his team are investigating the use of nanoparticles to communicate with cancer cells. Instead of delivering chemotherapy, their research focuses on using empty nanoparticles embedded with specific membrane proteins to send biological signals to tumor cells, instructing them to stop dividing. This work, particularly on solid tumors like Triple Negative breast cancer, is conducted in collaboration with physicians from the Rambam Health Care Campus. The interdisciplinary approach involves doctors, scientists, engineers, and students, allowing for a comprehensive study of both the cancer cells and their surrounding environment.

For PhD student Ofri Weizenblit, who carries a BRCA1 mutation, the breast cancer research is deeply personal, aiming to develop future treatment options. Singer is also driven by patient interactions, recalling a mother's plea for help for her child. He acknowledges the significant gap between laboratory success and human treatment, stating, "We know how to cure cancer in mice. In humans, we are still not doing it well enough." The urgency of patients and families awaiting better solutions fuels his continued research.

Zelnik-Manor sees a common thread in these diverse fields: identifying emerging scientific and technological areas that address real-world needs and investing in them proactively. The Technion aims to cultivate talent, knowledge, and an ecosystem that fosters world-changing innovations, emphasizing its role in disseminating knowledge and inspiring future advancements.